Cadrenal Therapeutics is developing tecarfarin, a novel oral and reversible vitamin K antagonist designed to provide safer anticoagulation for patients with implanted cardiac devices and rare cardiovascular conditions. This therapy addresses the lack of effective anticoagulation options for individuals with end-stage renal disease and atrial fibrillation, aiming to reduce the risk of heart attacks, strokes, and other thromboembolic events.
Funding
$4.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with implanted cardiac devices, such as Left Ventricular Assist Devices (LVADs) and mechanical heart valves (MHVs), or those with rare cardiovascular conditions like end-stage kidney disease (ESKD) with atrial fibrillation (AFib), lack effective anticoagulation therapies. Current options, like warfarin, have serious side effects and require cumbersome management, while direct oral anticoagulants (DOACs) have shown negative or inconclusive data for these specific patient populations.
Solution
Cadrenal Therapeutics is developing tecarfarin, a Phase 3-ready, novel oral and reversible vitamin K antagonist (VKA) designed to provide safer and more effective anticoagulation for underserved patients with implanted cardiac devices and rare cardiovascular conditions. Tecarfarin is metabolized through a different pathway than warfarin, mitigating common drug-drug interactions and kidney impairment issues prevalent in these patients. Clinical trial data suggests tecarfarin offers superior stability and time in therapeutic range compared to warfarin, potentially reducing the risk of strokes, heart attacks, bleeds, and deaths. The company is preparing for a pivotal Phase 3 trial in LVAD patients, with the goal of providing a superior alternative to existing anticoagulation therapies.
Target Audience
The primary target audience includes patients with implanted cardiac devices (LVADs, MHVs) or rare cardiovascular conditions such as end-stage kidney disease (ESKD) with atrial fibrillation (AFib) who require chronic anticoagulation.
Features
- Novel oral and reversible vitamin K antagonist (VKA)
- Designed to overcome the challenges associated with warfarin
- Metabolized via a different pathway than warfarin, reducing drug-drug interactions
- Efficacy is unaffected by kidney impairment
- Demonstrated superior stability and time in therapeutic range in Phase 2/3 clinical trials
- Preparing for a pivotal Phase 3 trial in LVAD patients